|Bid||175.04 x 1000|
|Ask||175.19 x 800|
|Day's Range||173.70 - 179.50|
|52 Week Range||59.29 - 331.68|
|Beta (5Y Monthly)||1.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 09, 2021 - Aug. 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||258.00|
On June 14, Novavax (NASDAQ: NVAX) announced that its recombinant nanoparticle coronavirus vaccine, NVX-CoV2373, had demonstrated 93% overall efficacy against coronavirus variants in phase 3 trials -- and that number shot up to 100% for severe or critical COVID-19. The vaccine candidate was also well-tolerated, with serious adverse events spread out equally between placebo and treatment groups. Shares fell about 10% after Novavax published the results.
Covid jabs for billions of humans will earn their makers billions of dollars. We look at the drug firms – led by Pfizer and Moderna – that are set to profit most in an unprecedented global vaccination drive
One scorching-hot company that you'll strongly want to consider adding to your portfolio this summer is social media superstar Pinterest (NYSE: PINS). To state the obvious, Pinterest benefited immensely from the pandemic. This meant spending more time posting about what interests them on Pinterest, as well as perusing the interests of others on the site.